

Vlad Ratziu

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3856547/vlad-ratziu-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

153
papers

11,807
citations

49
h-index

107
g-index

192
ext. papers

17,019
ext. citations

7.7
avg, IF

6.52
L-index

#	Paper	IF	Citations
153	Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. <i>Lancet, The</i> , 2001 , 357, 1069-75	40	1136
152	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020 , 73, 202-209	13.4	764
151	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020 , 158, 1999-2014.e1	13.3	748
150	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor- α and δ Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016 , 150, 1147-1159.e5	13.3	629
149	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , 2018 , 69, 896-904	13.4	550
148	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 2184-2196	40	425
147	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018 , 67, 1754-1767	11.2	376
146	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014 , 5, 4309	17.4	362
145	A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. <i>Journal of Hepatology</i> , 2013 , 59, 550-6	13.4	326
144	Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2006 , 6, 6	3	304
143	Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>Hepatology</i> , 2013 , 58, 1941-52	11.2	279
142	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017 , 112, 740-751	0.7	273
141	From NAFLD in clinical practice to answers from guidelines. <i>Journal of Hepatology</i> , 2013 , 59, 859-71	13.4	249
140	Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). <i>Lancet Infectious Diseases, The</i> , 2015 , 15, 397-404	25.5	244
139	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2021 , 384, 1113-1124	59.2	244
138	NAFLD and liver transplantation: Current burden and expected challenges. <i>Journal of Hepatology</i> , 2016 , 65, 1245-1257	13.4	237
137	Current efforts and trends in the treatment of NASH. <i>Journal of Hepatology</i> , 2015 , 62, S65-75	13.4	185

136	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021 , 592, 450-456	50.4	164
135	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018 , 155, 1140-1153	13.3	156
134	Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. <i>Contemporary Clinical Trials</i> , 2016 , 47, 356-653	2.3	142
133	Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. <i>Hepatology</i> , 2015 , 61, 41-5	11.2	136
132	Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard. <i>Journal of Hepatology</i> , 2013 , 58, 928-35	13.4	129
131	Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> , 2020 , 72, 892-905	11.2	116
130	Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2013 , 59, 675-83	13.4	115
129	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020 , 73, 505-515	13.4	113
128	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> , 2019 , 70, 1913-1927	11.2	111
127	Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest [®]) and transient elastography (FibroScan [®]). <i>Journal of Hepatology</i> , 2014 , 60, 706-14	13.4	85
126	Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. <i>Hepatology</i> , 2015 , 61, 1041-55	11.2	81
125	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. <i>Hepatology</i> , 2018 , 67, 2001-2012	11.2	79
124	From the Editor's Desk [□] <i>Journal of Hepatology</i> , 2020 , 73, 1001-1004	13.4	78
123	From the Editor's Desk [□] <i>Journal of Hepatology</i> , 2020 , 73, 475-478	13.4	78
122	From the Editor's Desk.... <i>Journal of Hepatology</i> , 2020 , 73, 745-748	13.4	78
121	From the Editor's Desk [□] <i>Journal of Hepatology</i> , 2021 , 74, 1277-1280	13.4	78
120	From the Editor's Desk [□] <i>Journal of Hepatology</i> , 2021 , 75, 257-260	13.4	78
119	Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. <i>World Journal of Gastroenterology</i> , 2013 , 19, 57-64	5.6	77

118	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , 2020 , 72, 14-24	13.4	75
117	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019 , 84, 105803	2.3	72
116	Fatty liver is an independent predictor of early carotid atherosclerosis. <i>Journal of Hepatology</i> , 2016 , 65, 95-102	13.4	67
115	Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , 2016 , 3, e000075	3.9	62
114	Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 193-203	6.1	62
113	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 970-985	18.8	54
112	Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. <i>BMC Gastroenterology</i> , 2011 , 11, 39	3	53
111	Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 616-629.e26	6.9	53
110	Pharmacological agents for NASH. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013 , 10, 676-85	24.2	52
109	Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. <i>Journal of Hepatology</i> , 2012 , 57, 541-8	13.4	52
108	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	51
107	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021 , 385, 1547-1558	59.2	50
106	Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity. <i>Gut</i> , 2017 , 66, 1688-1696	19.2	47
105	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2019 , 1, 188-198	10.3	46
104	Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 763-71.e1-6	6.9	46
103	Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 216-225.e5	6.9	46
102	A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. <i>Contemporary Clinical Trials</i> , 2020 , 88, 105889	2.3	45
101	Randomized study of asunaprevir plus pegylated interferon- λ and ribavirin for previously untreated genotype 1 chronic hepatitis C. <i>Antiviral Therapy</i> , 2013 , 18, 885-93	1.6	43

100	Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. <i>Hepatology</i> , 2019 , 70, 1841-1855	11.2	41
99	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	37
98	A critical review of endpoints for non-cirrhotic NASH therapeutic trials. <i>Journal of Hepatology</i> , 2018 , 68, 353-361	13.4	37
97	Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest [®]) and elastography (FibroScan [®]). <i>Journal of Hepatology</i> , 2014 , 61, 994-1003	13.4	36
96	Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020 , 72, 627-635	13.4	34
95	Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. <i>European Journal of Internal Medicine</i> , 2015 , 26, 30-6	3.9	30
94	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. <i>Journal of Hepatology</i> , 2018 , 69, 1365-1370	13.4	29
93	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 454-465	18.8	28
92	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020 , 98, 106175	2.3	28
91	Novel Pharmacotherapy Options for NASH. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 1398-405	4	27
90	The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease. <i>Clinics in Liver Disease</i> , 2014 , 18, 165-78	4.6	26
89	Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 80, e86-e94	3.1	26
88	Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014 , 61, 1220-7	13.4	24
87	Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison. <i>PLoS ONE</i> , 2016 , 11, e0163276	3.7	24
86	Non-pharmacological interventions in non-alcoholic fatty liver disease patients. <i>Liver International</i> , 2017 , 37 Suppl 1, 90-96	7.9	23
85	Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial. <i>Journal of Infectious Diseases</i> , 2013 , 208, 1000-7	7	23
84	Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020 , 72, 828-838	13.4	22
83	Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. <i>JHEP Reports</i> , 2020 , 2, 100143	14.3	20

82	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021 , 41, 1227-1242	7.9	20
81	Relationship Among Fatty Liver, Specific and Multiple-Site Atherosclerosis, and 10-Year Framingham Score. <i>Hepatology</i> , 2019 , 69, 1453-1463	11.2	19
80	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021 , 75, 770-785	13.4	19
79	Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 992-9.e2	6.9	18
78	Treatment of NASH with ursodeoxycholic acid: pro. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012 , 36 Suppl 1, S41-5	2.4	18
77	Is mipomersen ready for clinical implementation? A transatlantic dilemma. <i>Current Opinion in Lipidology</i> , 2013 , 24, 301-6	4.4	18
76	Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis. <i>Nature Metabolism</i> , 2020 , 2, 514-531	14.6	17
75	Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. <i>Transplantation</i> , 2019 , 103, 28-38	1.8	16
74	Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016 , 39, 428-327	2.7	15
73	Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1117-1127	6.1	14
72	Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis. <i>Scientific Reports</i> , 2020 , 10, 3850	4.9	13
71	Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 569-577	2.2	13
70	SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α 2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3429-36	5.9	13
69	Hepatic molecular effects of rosiglitazone in human non-alcoholic steatohepatitis suggest long-term pro-inflammatory damage. <i>Hepatology Research</i> , 2014 , 44, 1241-1247	5.1	13
68	European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?. <i>JHEP Reports</i> , 2021 , 3, 100234	10.3	13
67	TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021 , 161, 1475-1486	13.3	13
66	Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. <i>Future Oncology</i> , 2015 , 11, 2553-62	3.6	12
65	Performances of Elasto-FibroTest(\square), a combination between FibroTest(\square) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012 , 36, 455-63	2.4	12

64	Starting the battle to control non-alcoholic steatohepatitis. <i>Lancet, The</i> , 2015 , 385, 922-4	40	11
63	Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. <i>PLoS ONE</i> , 2017 , 12, e0189436	3.7	11
62	Predictive value of liver damage for severe early complications and survival after heart transplantation: A retrospective analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018 , 42, 416-426	2.4	10
61	Anti-hepatitis C virus antibody detection in oral fluid: influence of human immunodeficiency virus co-infection. <i>Journal of Clinical Virology</i> , 2013 , 58, 385-90	14.5	10
60	Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. <i>World Journal of Gastroenterology</i> , 2015 , 21, 5647-53	5.6	10
59	RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. <i>Cut</i> , 2021 , 70, 2359-2372	19.2	10
58	Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Microorganisms</i> , 2021 , 9,	4.9	10
57	Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini?". <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014 , 38, 432-9	2.4	9
56	Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. <i>BMJ Open</i> , 2015 , 5, e010017	3	9
55	Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis. <i>PLoS ONE</i> , 2015 , 10, e0134302	3.7	9
54	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020 , 29, 235-245	1.4	9
53	Liver Stiffness by Transient Elastography to Detect Porto-Sinusoidal Vascular Liver Disease With Portal Hypertension. <i>Hepatology</i> , 2021 , 74, 364-378	11.2	9
52	Non-alcoholic fatty liver disease: diagnosis and investigation. <i>Digestive Diseases</i> , 2014 , 32, 586-96	3.2	8
51	Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes. <i>Cell Reports Medicine</i> , 2020 , 1, 100154	18	8
50	Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. <i>Contemporary Clinical Trials</i> , 2020 , 97, 106174	2.3	8
49	Yet more evidence that MAFLD is more than a name change. <i>Journal of Hepatology</i> , 2021 , 74, 977-979	13.4	8
48	Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	8
47	The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 393-402	2.2	8

46	LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 308-320	6.1	8
45	Impact of steatosis and inflammation definitions on the performance of NASH tests. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 384-391	2.2	7
44	Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group. <i>Molecular Genetics and Metabolism</i> , 2020 , 129, 59-66	3.7	7
43	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2021 ,	13.4	7
42	EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. <i>Journal of Hepatology</i> , 2021 ,	13.4	6
41	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.. <i>Journal of Hepatology</i> , 2022 ,	13.4	5
40	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. <i>Journal of Hepatology</i> , 2021 ,	13.4	5
39	Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021 ,	13.3	5
38	Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 998-1007	2.2	5
37	Real-World Burden of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1020-1029.e7	6.9	5
36	Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. <i>Journal of Hepatology</i> , 2021 , 75, 1292-1300	13.4	5
35	Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 889-902	18.8	5
34	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.. <i>Journal of Hepatology</i> , 2021 ,	13.4	4
33	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. <i>PLoS ONE</i> , 2020 , 15, e0242306	3.7	4
32	Real-life Perception and Practice Patterns of NAFLD/NASH in Romania: Results of a Survey Completed by 102 Board-certified Gastroenterologists. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2016 , 25, 183-9	1.4	4
31	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.. <i>JHEP Reports</i> , 2022 , 4, 100409	10.3	4
30	Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. <i>Medical Decision Making</i> , 2020 , 40, 830-845	2.5	4
29	The painful reality of end-stage liver disease in NASH. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 8-10	18.8	3

28	Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. <i>Science Translational Medicine</i> , 2021 , 13, eabe8939	17.5	3
27	Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. <i>Journal of Hepatology</i> , 2021 ,	13.4	3
26	Arterial hypertension as an uninvited player in hepatic stiffness?. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 311, G942-G944	5.1	3
25	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. <i>JHEP Reports</i> , 2021 , 3, 100298	10.3	3
24	External validation of an algorithm combining multi-analyte blood tests (FibroTest-LCR1-LCR2) to identify subjects at risk of hepatocellular carcinoma in patients with chronic liver disease. <i>GastroHep</i> , 2019 , 1, 146-153	1	2
23	Benefit of Treatment With Sebelipase-Alfa in a 63-Year-Old Patient With Advanced Liver and Atherosclerotic Disease Due to Lysosomal Acid Lipase Deficiency (LAL-D). <i>American Journal of Gastroenterology</i> , 2018 , 113, 443-445	0.7	2
22	Targeting non-alcoholic fatty liver disease through 11- β SD1 inhibition. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 354-6	18.1	2
21	Pharmacological agents for nonalcoholic steatohepatitis. <i>Hepatology International</i> , 2013 , 7 Suppl 2, 833-838	8.8	2
20	Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery.. <i>Hepatology</i> , 2022 ,	11.2	2
19	A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. <i>Advances in Therapy</i> , 2020 , 37, 4627-4640	4.1	2
18	Reply to "Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease". <i>Journal of Hepatology</i> , 2016 , 65, 1267-1268	13.4	2
17	From the Editor's Desk \square <i>Journal of Hepatology</i> , 2021 , 74, 1-4	13.4	2
16	coreNASH: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment. <i>Hepatology Communications</i> , 2021 , 5, 774-785	6	2
15	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.. <i>JHEP Reports</i> , 2022 , 4, 100477	10.3	2
14	Screening studies of transient elastography and FibroTest in the general population. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 246	18.8	1
13	Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. <i>Annals of Internal Medicine</i> , 2013 , 159, 370-1	8	1
12	Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease.. <i>Frontiers in Nutrition</i> , 2021 , 8, 774030	6.2	1
11	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease		1

10	Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis. <i>Clinical Liver Disease</i> , 2021 , 17, 398-400	40	1
9	Improving NASH with a little help from thymomimetics. <i>Lancet, The</i> , 2019 , 394, 1970-1972	40	1
8	Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.. <i>Biomedicines</i> , 2022 , 10,	4.8	1
7	Breakthroughs in therapies for NASH and remaining challenges.. <i>Journal of Hepatology</i> , 2022 , 76, 1263-1278	13.4	1
6	External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B 2022 , 1, 604-617		0
5	From the Editor's Desk <i>Journal of Hepatology</i> , 2020 , 73, 1299-1302	13.4	
4	Clinical endpoints are necessary in the interim analysis of REGENERATE - Authors' reply. <i>Lancet, The</i> , 2020 , 396, 663-664	40	
3	How to best diagnose NAFLD/NASH? 2016 , 111-123		
2	Reply to Jindal et al.. <i>Hepatology</i> , 2022 ,	11.2	
1	Reply to Pattou et al.. <i>Hepatology</i> , 2022 ,	11.2	